{"title":"HOXC6-TIMELESS轴：揭示膀胱癌的新治疗策略。","authors":"Meng-Meng Shi, Ming-Yue Guan, Shi Li, Jie-Yu Guo, Xing-Zhen Chen, Jing-Feng Tang, Ce-Fan Zhou","doi":"10.5306/wjco.v16.i7.108071","DOIUrl":null,"url":null,"abstract":"<p><p>Bladder cancer (BLCA) is a highly invasive malignancy with limited targeted therapies. Lu <i>et al</i> reveal the oncogenic role of HOXC6 in BLCA by showing its elevated mRNA and protein levels in cancerous tissues. Silencing HOXC6 significantly inhibits BLCA cell proliferation, migration and invasion, induces apoptosis and arrests the cell cycle at G0/G1. In addition, HOXC6 also regulates pathways related to chemical carcinogenesis and reactive oxygen species, with a strong association with the target gene TIMELESS, supported by binding signals in its promoter region. Here, we discuss the role of HOXC6 as a potential biomarker and therapeutic target, contributing to a deeper understanding of the HOXC6-TIMELESS axis and its implications for advancing BLCA research and therapy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 7","pages":"108071"},"PeriodicalIF":3.2000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305105/pdf/","citationCount":"0","resultStr":"{\"title\":\"HOXC6-TIMELESS axis: Unveiling novel therapeutic strategies in bladder cancer.\",\"authors\":\"Meng-Meng Shi, Ming-Yue Guan, Shi Li, Jie-Yu Guo, Xing-Zhen Chen, Jing-Feng Tang, Ce-Fan Zhou\",\"doi\":\"10.5306/wjco.v16.i7.108071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Bladder cancer (BLCA) is a highly invasive malignancy with limited targeted therapies. Lu <i>et al</i> reveal the oncogenic role of HOXC6 in BLCA by showing its elevated mRNA and protein levels in cancerous tissues. Silencing HOXC6 significantly inhibits BLCA cell proliferation, migration and invasion, induces apoptosis and arrests the cell cycle at G0/G1. In addition, HOXC6 also regulates pathways related to chemical carcinogenesis and reactive oxygen species, with a strong association with the target gene TIMELESS, supported by binding signals in its promoter region. Here, we discuss the role of HOXC6 as a potential biomarker and therapeutic target, contributing to a deeper understanding of the HOXC6-TIMELESS axis and its implications for advancing BLCA research and therapy.</p>\",\"PeriodicalId\":23802,\"journal\":{\"name\":\"World journal of clinical oncology\",\"volume\":\"16 7\",\"pages\":\"108071\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12305105/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World journal of clinical oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5306/wjco.v16.i7.108071\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i7.108071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
HOXC6-TIMELESS axis: Unveiling novel therapeutic strategies in bladder cancer.
Bladder cancer (BLCA) is a highly invasive malignancy with limited targeted therapies. Lu et al reveal the oncogenic role of HOXC6 in BLCA by showing its elevated mRNA and protein levels in cancerous tissues. Silencing HOXC6 significantly inhibits BLCA cell proliferation, migration and invasion, induces apoptosis and arrests the cell cycle at G0/G1. In addition, HOXC6 also regulates pathways related to chemical carcinogenesis and reactive oxygen species, with a strong association with the target gene TIMELESS, supported by binding signals in its promoter region. Here, we discuss the role of HOXC6 as a potential biomarker and therapeutic target, contributing to a deeper understanding of the HOXC6-TIMELESS axis and its implications for advancing BLCA research and therapy.
期刊介绍：
The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
